Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LGVN NASDAQ:NCEL NASDAQ:QNCX NASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLGVNLongeveron$0.86+0.4%$0.91$0.48▼$1.80$19.92M-0.314.00 million shs43,029 shsNCELNLS Pharmaceutics$3.24$2.81$1.83▼$30.80$17.33M1.0181,351 shs4,693 shsQNCXQuince Therapeutics$1.23-5.4%$1.16$0.80▼$45.50$20.05M1.457.52 million shs192,728 shsSBFMSunshine Biopharma$1.07-0.9%$1.06$0.95▼$2.43$5.25M1.3737,655 shs8,766 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLGVNLongeveron-2.54%+0.16%-26.57%+66.04%-42.83%NCELNLS Pharmaceutics-2.41%-26.53%+55.77%+16.97%-80.94%QNCXQuince Therapeutics+6.56%-0.76%-20.25%-6.54%-87.50%SBFMSunshine Biopharma-0.01%+12.22%+3.84%-10.01%-14.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLGVNLongeveron$0.86+0.4%$0.91$0.48▼$1.80$19.92M-0.314.00 million shs43,029 shsNCELNLS Pharmaceutics$3.24$2.81$1.83▼$30.80$17.33M1.0181,351 shs4,693 shsQNCXQuince Therapeutics$1.23-5.4%$1.16$0.80▼$45.50$20.05M1.457.52 million shs192,728 shsSBFMSunshine Biopharma$1.07-0.9%$1.06$0.95▼$2.43$5.25M1.3737,655 shs8,766 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLGVNLongeveron-2.54%+0.16%-26.57%+66.04%-42.83%NCELNLS Pharmaceutics-2.41%-26.53%+55.77%+16.97%-80.94%QNCXQuince Therapeutics+6.56%-0.76%-20.25%-6.54%-87.50%SBFMSunshine Biopharma-0.01%+12.22%+3.84%-10.01%-14.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLGVNLongeveron 2.33Hold$5.50543.27% UpsideNCELNLS Pharmaceutics 1.00SellN/AN/AQNCXQuince Therapeutics 1.71Reduce$65.005,184.55% UpsideSBFMSunshine Biopharma 2.00Hold$7.00554.21% UpsideCurrent Analyst Ratings BreakdownLatest SBFM, QNCX, LGVN, and NCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026LGVNLongeveron HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.005/1/2026QNCXQuince Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SBFMSunshine Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLGVNLongeveron$1.20M16.58N/AN/A$0.25 per share3.42NCELNLS PharmaceuticsN/AN/AN/AN/A$1.59 per shareN/AQNCXQuince TherapeuticsN/AN/AN/AN/A($6.41) per shareN/ASBFMSunshine Biopharma$36.31M0.14N/AN/A$4.69 per share0.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLGVNLongeveron-$22.70M-$1.28N/AN/AN/A-1,893.58%-199.79%-143.21%5/13/2026 (Estimated)NCELNLS Pharmaceutics-$8.30MN/AN/AN/AN/AN/AN/AN/AN/AQNCXQuince Therapeutics-$83.98M-$16.90N/AN/AN/AN/A-372.88%-62.36%5/13/2026 (Estimated)SBFMSunshine Biopharma-$5.97M-$1.48N/AN/AN/A-17.86%-27.14%-21.14%N/ALatest SBFM, QNCX, LGVN, and NCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026LGVNLongeveron-$0.19N/AN/AN/A$0.35 millionN/A5/13/2026Q1 2026QNCXQuince Therapeutics-$1.5580N/AN/AN/AN/AN/A4/3/2026Q4 2025SBFMSunshine Biopharma-$0.27-$0.46-$0.19-$0.46$10.00 million$8.58 million3/17/2026Q4 2025LGVNLongeveron-$0.42-$0.22+$0.20-$0.22$0.11 million$0.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLGVNLongeveronN/AN/AN/AN/AN/ANCELNLS PharmaceuticsN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLGVNLongeveron0.031.331.33NCELNLS PharmaceuticsN/A0.760.76QNCXQuince TherapeuticsN/A0.530.53SBFMSunshine BiopharmaN/A4.172.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLGVNLongeveron10.01%NCELNLS PharmaceuticsN/AQNCXQuince Therapeutics30.75%SBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipLGVNLongeveron11.20%NCELNLS Pharmaceutics16.40%QNCXQuince Therapeutics20.30%SBFMSunshine Biopharma0.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLGVNLongeveron2023.27 million20.66 millionNot OptionableNCELNLS Pharmaceutics65.35 million4.47 millionNot OptionableQNCXQuince Therapeutics6016.30 million12.99 millionOptionableSBFMSunshine Biopharma34.91 million4.90 millionNot OptionableSBFM, QNCX, LGVN, and NCEL HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals (NASDAQ:TARS) and Sunshine Biopharma (NASDAQ:SBFM) Critical SurveyMay 8 at 4:36 AM | americanbankingnews.comSunshine Biopharma Delays Annual SEC FilingApril 14, 2026 | theglobeandmail.comSunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior YearApril 6, 2026 | accessnewswire.comASunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)October 28, 2025 | accessnewswire.comASunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidoneOctober 28, 2025 | msn.comSunshine Biopharma stock rises after Health Canada approval for DomperidoneOctober 28, 2025 | za.investing.comSunshine Biopharma Inc.: Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 28, 2025 | finanznachrichten.deSunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 28, 2025 | accessnewswire.comASunshine Biopharma Inc.: Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineOctober 21, 2025 | finanznachrichten.deSunshine Biopharma announces commercial launch of doxycycline in CanadaOctober 20, 2025 | msn.comSunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineOctober 20, 2025 | accessnewswire.comASunshine Biopharma stock soars after launch of cholesterol drug PravastatinOctober 16, 2025 | au.investing.comSunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian UnitOctober 16, 2025 | msn.comSunshine Biopharma Launches Cholesterol Fighting Medicine PravastatinOctober 16, 2025 | accessnewswire.comASunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level ExecutionOctober 14, 2025 | finanznachrichten.deSunshine Biopharma allocates $5M for investment in bitcoinOctober 14, 2025 | msn.comSunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)October 14, 2025 | accessnewswire.comASunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)October 14, 2025 | accessnewswire.comASunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury ResilienceOctober 14, 2025 | accessnewswire.comASunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus InfectionsOctober 9, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBFM, QNCX, LGVN, and NCEL Company DescriptionsLongeveron NASDAQ:LGVN$0.86 +0.00 (+0.38%) As of 12:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.NLS Pharmaceutics NASDAQ:NCEL$3.24 0.00 (0.00%) As of 11:47 AM EasternNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Quince Therapeutics NASDAQ:QNCX$1.23 -0.07 (-5.38%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Sunshine Biopharma NASDAQ:SBFM$1.07 -0.01 (-0.92%) As of 11:58 AM Eastern This is a fair market value price provided by Massive. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
